Treatment of HCC with Claudin-1 specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
Fiche publication
Date publication
octobre 2022
Journal
Journal of hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr DAVIDSON Irwin, Pr LAQUERRIERE Patrice, Dr LUPBERGER Joachim, Pr PESSAUX Patrick, Dr CROUCHET Emilie
Tous les auteurs :
Roehlen N, Muller M, Nehme Z, Crouchet E, Jühling F, Del Zompo F, Cherradi S, Duong FHT, Almeida N, Saviano A, Fernández-Vaquero M, Riedl T, El Saghire H, Durand SC, Ponsolles C, Oudot MA, Martin R, Brignon N, Felli E, Pessaux P, Lallement A, Davidson I, Bandiera S, Thumann C, Marchand P, Moll S, Nicolay B, Bardeesy N, Hoshida Y, Heikenwälder M, Iacone R, Toso A, Meyer M, Elson G, Schweighoffer T, Teixeira G, Zeisel MB, Laquerriere P, Lupberger J, Schuster C, Mailly L, Baumert TF
Lien Pubmed
Résumé
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Despite new treatment approvals, treatment response and prognosis of patients with advanced HCC remain poor. Claudin-1 (CLDN1) is a membrane protein expressed not only at tight junctions but also non-junctionally such as the basolateral membrane of the human hepatocyte. While CLDN1 within tight junctions is well characterized, the role of non-junctional CLDN1 and its role as a therapeutic target in HCC remains unexplored.
Mots clés
CLDN1, HCC, Liver cancer, plasticity, resistance, stemness, tight junction, tumor immune microenvironment
Référence
J Hepatol. 2022 10 26;: